Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06240091
Other study ID # W-DISC-002
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date March 13, 2024
Est. completion date June 1, 2024

Study information

Verified date April 2024
Source Woebot Health
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overarching goal of this study is to establish initial proof of mechanism for precision interventions in an adult population.


Description:

This exploratory single-arm trial will provide initial learning on the current implementation of precision interventions and generate data and hypotheses to inform the exploration of future interventions by identifying mechanisms and moments in the user journey to target. The DISC-MA app uses a relational agent (Woebot) to engage users in conversations. Eligible participants will be assigned to use DISC-MA, in which Woebot selects from a list of responses based on natural language processing. Participants will receive instructions on downloading and using the DISC-MA app in order to access the intervention. Participants will use the app as instructed and will complete assessments for the primary endpoint as Week 4 (EOT) with additional measures being collected as Baseline, Week 1, and Week 2. Results from this study will provide data on baseline participant clinical and psychological characteristics and their engagement with DISC-MA, and associations between the two.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 203
Est. completion date June 1, 2024
Est. primary completion date June 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Must be 18-75 years of age 2. Must own or have regular access to a smartphone with a recent operating system installed (Android: OS 8.0 or higher, Apple: iOS 13.0 or higher) with reliable Wi-Fi access or sufficient data plan to engage with assigned treatment condition for the duration of the study 3. Must be available and committed to engage with the program and complete assessments for a 4-week duration 4. Must be able to read and write in English 5. Must have primary residence in the United States 6. Must have mild or greater symptoms of depression and/or anxiety at Screening/Baseline, indicated by a score > 4 on the Patient Health Questionnaire (PHQ-8) and/or Generalized Anxiety Disorder (GAD-7) Exclusion Criteria: 1. Current suicidal ideation with a plan and/or intent or a suicide attempt within the past 12 months 2. Previous Woebot use 3. Involuntary inpatient psychiatric hospitalization any time within the past 30 days 4. Lifetime diagnosis of bipolar disorder 5. Lifetime diagnosis of a psychotic disorder

Study Design


Related Conditions & MeSH terms


Intervention

Device:
DISC-MA
DISC-MA is a digital program that utilizes elements from validated psychotherapies (e.g., cognitive behavioral therapy), with a relational agent (Woebot) that engages users in conversations with responses that are selected from a list based on natural language processing.

Locations

Country Name City State
United States Woebot Investigational Site San Francisco California

Sponsors (1)

Lead Sponsor Collaborator
Woebot Health

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Working Alliance Inventory-Short Revised (WAI-SR), Total Scale Measure of working alliance. A 12-item measure that assesses three key aspects of the therapeutic alliance: (a) agreement on the tasks of therapy, (b) agreement on the goals of therapy, and (c) development of an affective bond. For the purposes of the study, the word "therapist" was replaced with "Woebot". Total mean scores range from 1-5, with higher scores indicating greater alliance between the participant and Woebot. 1 week and Post-treatment at 4 weeks
See also
  Status Clinical Trial Phase
Completed NCT04122482 - An Online Course for Improving Knowledge and Access to Mental Health Accommodations in Canadian Enterprises N/A
Completed NCT04085861 - Mental Health in Dancers; an Intervention Study N/A
Recruiting NCT06060210 - Impact of Ketamine On Depressive Symptoms In Patients Undergoing Lumbo-peritoneal Shunt Insertion Phase 4
Active, not recruiting NCT04588883 - Strengthening Families Living With HIV in Kenya N/A
Recruiting NCT06065787 - NeuroGlove Anxiety and Depression Study N/A
Active, not recruiting NCT04583891 - Mobile Apps to Reduce Distress in Breast Cancer Survivors Using an Adaptive Design N/A
Completed NCT05554042 - Kintsugi Voice Device Study
Not yet recruiting NCT06162624 - Pilot Effectiveness Trial of an ACT Self-help Workbook Tailored Specifically for Prisons N/A
Completed NCT02954250 - Mindfulness Based Cognitive Therapy for Depression and Cognitive Inhibition in Suicide Early Phase 1
Recruiting NCT05647499 - Evaluating the Back 2 School Program in a Norwegian Setting: A Multicenter Pilot Study N/A
Completed NCT03980873 - Cognitive-Behavioral Therapy for Young Adult Lesbian, Gay and Bisexual: Transdiagnostic Minority Stress Approach N/A
Completed NCT04422327 - The Impact of a Combination of Bifidobacterium Longum 35624® and 1714™ Strains in Adults With Irritable Bowel Syndrome Phase 1/Phase 2
Completed NCT05368155 - Chronic Pelvic Pain and Education Skills Training for Women Veterans N/A
Completed NCT05455905 - Voice Biomarkers Predictive of Depression and Anxiety
Completed NCT03272516 - Mindfulness Based Cognitive Therapy (MBCT) for Primary Care Patients N/A
Not yet recruiting NCT06027047 - Breakthrough Anxiety and Sleep Evaluation Using Linked Devices and Smartphone Application Onar (BASEL)
Not yet recruiting NCT05535101 - Non-invasive Brain Stimulation in Patients With Methamphetamine Use Disorder N/A
Recruiting NCT04418115 - Fatigue as a Late Effect in Breast Cancer Survivors - is Acupuncture a Treatment Option? N/A
Completed NCT04905524 - Activity Changes in Irritable Bowel Syndrome (IBS), Anxiety, and Depression Following the Use of Viome Precision Nutrition Program (VPNP) N/A
Recruiting NCT03953118 - Azithromycin for Meibomian Gland Disease Phase 4